Sonnet BioTherapeutics Competitors and Similar CompaniesClear all
Sonnet BioTherapeutics's competitors and similar companies include ImmunityBio, Cullinan Oncology, MABION and Forbius.
 Sonnet BioTherapeutics Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company. |  ImmunityBio ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. |  Cullinan Oncology Cullinan Oncology is a company that develops cancer treatments and a portfolio of oncology therapeutics. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. |  Forbius Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases. | |
Founding Date | Founding Date 2011 | Founding Date 2014 | Founding Date 2016 | Founding Date 2007 | Founding Date 2011 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Princeton, US HQ | Locations Culver City, US HQ San Diego, US Woburn, US | Locations Cambridge, US HQ | Locations Konstantynów Łódzki, PL HQ | Locations Austin, US HQ Montréal, CA |
Employees | Employees 12 | Employees 16116% increase | Employees 11131% increase | Employees 95 | Employees 811% decrease |
Valuation ($) | Valuation ($) 2.9 m | Valuation ($) 4.3 b | Valuation ($) 981 m | Valuation ($) 21.7 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $1m (FY, 2025) | Revenue (est.) $113.3m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) zł15.8m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $753k (FY, 2025) | Cost of goods N/A | Cost of goods zł24.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $112.5m (FY, 2025) | Gross profit N/A | Gross profit (zł7.2m) (FY, 2025) | Gross profit N/A |
Net income | Net income ($16m) (FY, 2025) | Net income ($351.5m) (FY, 2025) | Net income ($219.9m) (FY, 2025) | Net income (zł62.6m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 750k | Total funding raised N/A | Total funding raised $ 248.5m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmunityBio
HQ
Culver City, US
Employees
161↑ 16% increase
ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.
View companyCullinan Oncology
HQ
Cambridge, US
Employees
111↑ 31% increase
Cullinan Oncology is a company that develops cancer treatments and a portfolio of oncology therapeutics.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View companyForbius
HQ
Austin, US
Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases.
View company